Stefanie C. M. Burleson

Stefanie C. M. Burleson

Auto-generated profile, based on publicly available information

Stefanie C. M. Burleson

Burleson Research Technologies Inc., Morrisville, North Carolina 27560

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2017 in International Journal of Toxicology
Verified
Journal Article
Open access
PDF file
JPJulia Parrish-Novak
Julia Parrish-Novak
KBKelly Byrnes-Blake
Kelly Byrnes-Blake
NLNarine Lalayeva
Narine Lalayeva
SBStefanie Burleson
Stefanie Burleson
JFJanean Fidel
Janean Fidel
DMDennis M. Miller
Dennis M. Miller
BLZ-100 is a single intravenous use, fluorescent imaging agent that labels tumor tissue to enable more complete and precise surgical resection. It is composed of a chlorotoxin peptide covalently bound to the near-infrared fluorophore indocyanine green. BLZ-100 is in clinical development for intraoperative visualization of human tumors. The nonclinical safety and pharmacokinetic (PK) profile of BLZ-100 was evaluated in mice, rats, canines, and nonhuman primates (NHP). Single bolus intravenous administration of BLZ-100 was well tolerated, and no adverse changes were observed in cardiovascular safety pharmacology, PK, and toxicology studies in rats and NHP. The single-dose no-observed-adverse-effect-levels (NOAELs) were 7 mg (28 mg/kg) in rats and 60 mg (20 mg/kg) in NHP, corresponding to peak concentration values of 89 400 and 436 000 ng/mL and area-under-the-curve exposure values of 130 000 and 1 240 000 h·ng/mL, respectively. Based on a human imaging dose of 3 mg, dose safety margins are >100 for rat and monkey. BLZ-100 produced hypersensitivity reactions in canine imaging studies (lethargy, pruritus, swollen muzzle, etc). The severity of the reactions was not dose related. In a follow-up study in dogs, plasma histamine concentrations were increased 5 to 60 minutes after BLZ-100 injection; this coincided with signs of hypersensitivity, supporting the conclusion that the reactions were histamine based. Hypersensitivity reactions were not observed in other species or in BLZ-100 human clinical studies conducted to date. The combined imaging, safety pharmacology, PK, and toxicology studies contributed to an extensive initial nonclinical profile for BLZ-100, supporting first-in-human clinical trials.

8 June 2018
Verified
Book Chapter
Closed access
PDF file
SBStefanie C. M. Burleson
Stefanie C. M. Burleson
WFWendy Jo Freebern
Wendy Jo Freebern
FBFlorence G. Burleson
Florence G. Burleson
GBGary R. Burleson
Gary R. Burleson
VJVictor J. Johnson
Victor J. Johnson
RLRobert W. Luebke
Robert W. Luebke

22 February 2019 in Toxicological Sciences
Verified
Journal Article
Open access
PDF file
GRGautham K Rao
Gautham K Rao
RPRodney A Prell
Rodney A Prell
SLSteven T Laing
Steven T Laing
SBStefanie C M Burleson
Stefanie C M Burleson
ANAllen Nguyen
Allen Nguyen
WHWendy G Halpern
Wendy G Halpern
A theoretical safety concern proposed in the influenza literature is that therapeutic antiviral antibodies could have the potential for antibody-dependent enhancement (ADE) of infection and disease. ADE may occur when virus-specific antibodies at subtherapeutic, nonneutralizing concentrations facilitate virus uptake and, in some cases, enhance replication, which can lead to an exacerbation of virus-mediated disease. Alternatively, ADE may occur due to antibody-dependent complement activation exacerbating virus-mediated disease in the absence of increased replication. As a result of this theoretical safety concern, safety assessment of anti-influenza antibodies may include an in vivo evaluation of ADE of infection and/or disease. These studies were conducted to investigate the potential of MHAB5553A, a broadly specific, neutralizing therapeutic anti-influenza B antibody, to elicit ADE of infection and disease in mouse models of influenza B infection. In parallel studies, female DBA/2J mice were infected with either influenza B/Victoria/504/2000 or influenza B/Brisbane/60/2008 representing distinct lineages. Assessment of ADE was based on an integration of results from multiple endpoints, including infectious lung viral titers and genomes, body weight, mortality, lung weight, and histopathology. In these studies, the high dose of 15 mg/kg MHAB5553A resulted in substantial attenuation of influenza pneumonia, with more modest effects at 1.5 mg/kg; whereas MHAB5553A treatment at 0.15 or 0.015 mg/kg was generally comparable to vehicle-treated controls. Our results demonstrate that MHAB5553A across a broad range of doses did not enhance primary influenza B infection or disease in this model, and represent a nonclinical de-risking of the ADE potential with this antibody.

1 January 2015
Verified
Book Chapter
Closed access
GBGary R. Burleson
Gary R. Burleson
SBStefanie C.M. Burleson
Stefanie C.M. Burleson
FBFlorence G. Burleson
Florence G. Burleson

1 January 2015
Verified
Book Chapter
Closed access
SBStefanie C.M. Burleson
Stefanie C.M. Burleson
RFRobert B. Fick
Robert B. Fick
MMMark D. Mannie
Mark D. Mannie
SOStephen G. Olmstead
Stephen G. Olmstead
MSMichael R. Van Scott
Michael R. Van Scott

29 March 2017
Verified
Book Chapter
Closed access
PDF file
GBGary R. Burleson
Gary R. Burleson
SBStefanie C. M. Burleson
Stefanie C. M. Burleson
FBFlorence G. Burleson
Florence G. Burleson